MedDataX Logo

Resiliency Programming for Caregivers of Children With Learning and Attentional Difficulties

NCT06492278 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-07-30

No results posted yet for this study

Summary

This is a randomized open pilot trial enrolling up to 40 co-primary caregivers of children with LAD. Participants will be randomized to receive either mind-body resiliency group (SMART-LAD, intervention) or an evidence-based group intervention Health Education Program (HEP, control) which is a multiple behavior change program that addresses sleep, exercise, nutrition, substance use, and working with one's healthcare team. Both the SMART-3RP and HEP programs have been modified based on adaptions from our previous qualitative study.

Conditions

  • Parenting
  • Stress
  • Learning Disabilities, Child
  • Attention Difficulties

Interventions

BEHAVIORAL

SMART-3RP

The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.

BEHAVIORAL

Health Education Program

This is a multiple behavior change program that addresses sleep, exercise, nutrition, substance use, and working with one's healthcare team.

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Elyse R Park, PhD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-03-17
Completion
2025-03-17

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06492278 on ClinicalTrials.gov